FIELD: medicine.
SUBSTANCE: group of inventions relates to the treatment of diseases associated with tubulin carboxypeptidase (TCP) and the screening of compounds suitable for the treatment of such diseases. The use of an inhibitor of the expression or activity of the vasohibin/SVBP (small vasohibin binding protein) complex is provided for the treatment of a disease associated with the tubulin carboxypeptidase tubulin deirosination/tyrosination cycle in a subject who requires it. Also the use of a pharmaceutical composition containing an inhibitor of the expression or activity of the vasohibin/SVBP complex for the treatment of the abovementioned disease is proposed. The TCP-associated disease is a neurological disorder (particularly multiple sclerosis, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, and Alzheimer's disease) or a cardiovascular disease (particularly myocardial infarction, myocardial infarction inducing vascular dysfunction, heart failure, cardiomyopathy and dystrophinopathy). In addition, a method for screening a plurality of candidate compounds useful in the treatment of a disease associated with the tubulin carboxypeptidase tubulin deterosination/tyrosination cycle is provided, the method comprises the steps of (a) testing each of the candidate compounds to determine its ability to inhibit the activity or expression of the vasohibin/SVBP complex, and (b) and positive selection of candidate compounds capable of inhibiting the said activity or expression of the vasohibin/SVBP complex. The inventors successfully identified vasohibin/SVBP complexes as TCP enzymes and investigated the effect of their negative feedback regulation on neuronal physiology.
EFFECT: use of the group of inventions makes it possible to modulate the activity of TCP enzymes in a pathological state.
11 cl, 19 dwg, 2 tbl, 7 ex
